Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase... | February 2, 2023

Related Keywords

China ,Japan ,United States ,Canada ,Hong Kong ,Philadelphia ,Pennsylvania ,Macau , ,International Financial Reporting Standards ,European Commission ,Arrowhead Pharmaceuticals Inc ,Exchange Commission ,China National Medical Products Administration ,Nimbus Therapeutics ,Takeda Pharmaceutical Company Limited ,Constant Exchange Rate ,Costa Saroukos ,Launch Products ,Free Cash Flow ,Derived Therapies ,Emerging Markets ,Major Depressive Disorder ,With Phase ,Biologics License ,National Medical Products Administration ,Arrowhead Pharmaceuticals ,Cash Flow ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Score Revenue ,Core Operating Profit ,Core Net Profit ,Net Debt ,Free Cash ,Takeda Pharmaceutical Company Limited Stock Exchange ,News ,Information ,Press Release ,Nnounced ,Agreement ,Ith ,Cnimbus ,Herapeutics ,N ,December ,O ,Cquire ,Potential ,Tyk2 ,End ,Hutchmed ,January ,Ighly ,Mural ,Yrosine 4502 Jp3463000004 ,